The use of salvage nivolumab-ipilimumab in metastasis ccRCC after anti-PD-1/PD-L1 only received limited activity with a 10% response rate, and part of patients developing grade ≥ 3 immune-related adverse events (11). The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.